Posted on September 20, 2017

Following the signing of the agreement between Metabolon, Inc and the Anti-Doping Lab Qatar on 3 May 2017, efforts have been focused on establishing the Metabolon platform that will enable ADLQ to offer high throughput metabolomics services based in Doha.

Both parties have been involved in the offsite and onsite training of ADLQ staff who will run the platform that is currently anticipated to receive client samples in November 2017. In order to inaugurate the completion of the platform, a Metabolomics Science Workshop was held last Tuesday the 17th of September at ADLQ. The one day workshop attracted more than 70 attendees from overseas as well as from Qatar. Local attendees represented several research institutions in Doha, including QF, QBRI, Sidra, HMC, WCMC and others. Metabolon, Inc. is the world’s leading health technology company advancing metabolomics for precision medicine and life sciences research. “The collaboration with ADLQ allows us to serve a new, significant market,” said Metabolon CEO Dr John Ryals.

ADLQ, as one of the premier testing laboratories in the region, is very proud to be part of this collaboration that will indeed facilitate Metabolomics research in this part of the world. “ADLQ, as a Qatari institute, is always concerned with projects and services that add value to the country and to the region, in terms of its impact on health and wellness. We have the required expertise and state-of-the-art instrumentation for the job. So it was an ideal collaboration“, said the GM, Dr Mohammed Alsayrafi. The session opened with a welcoming address from the partners, Dr Mohammed Alsayrafi from ADLQ, Dr Carlos Malpica from Metabolon and Prof Khaled Machaca from Weil Cornell Medicine – Qatar.

Dr Machaca said: “The Metabolon-ADLQ platform offers local researchers with cutting edge technology to advance precision medicine in Qatar. It also represents a model of a productive national collaborative effort in Qatar, under the leadership of ADLQ to consolidate expertise and resources from multiple national stakeholders toward a communal benefit.” In addition, Dr Hadi Abdelrahim, from Qatar Foundation has commented saying “The ADLQ metabolomics platform will be used to help predict disease risk and monitor their evolution. The centralized model fits well the research coordination effort that we envision as a way forward. It is in this sense an important complement to the existing research resources already set up at WCMC and SIDRA (proteomics and genomics), Qatar biobank, and QBRI”.

The workshop featured renowned scientists and topics ranging from ‘big data’ science, such as population health studies utilizing the power of Precision Metabolomics, to the delivery of metabolomics to the individual in the form of Precision Medicine. The workshop was also intended to bring knowledge to researchers who could potentially benefit from Metabolon metabolomics services and promote collaborative research.   “This collaboration will not only help to establish expertise in advanced metabolomics research but will also serve as a valuable training platform for local scientists using high-end instrumentation”, commented Dr Aishah Latiff, who is responsible for the Metabolon platform services at ADLQ.